Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sabatolimab, an antibody targeting TIM-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tusamitamab, an antibody targeting CEACAM5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Briakinumab, an antibody targeting IL-12/23p40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Maftivimab, an antibody targeting Zaire Ebolavirus Glycoprotein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Edrecolomab, an antibody targeting EPCAM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Arcitumomab, an antibody targeting CEA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abciximab, an antibody targeting ITGA2B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Basiliximab, an antibody targeting IL2RA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Satumomab, an antibody targeting TAG72.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ibritumomab, an antibody targeting CD20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Efalizumab, an antibody targeting ITGAL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ibalizumab, an antibody targeting CD4.